2 results match your criteria: "Dr. Siyami Ersek Chest Heart and Vascular Surgery Training and Research Hospital[Affiliation]"
[Current Use of Sodium Glucose Co-transporter 2 Inhibitors in Heart Failure Therapy].
Turk Kardiyol Dern Ars
September 2024
Department of Cardiology, Dokuz Eylul University Faculty of Medicine, Izmir, Türkiye.
Article Synopsis
- Sodium-glucose cotransporter-2 inhibitors (SGLT2i) help lower blood glucose and sodium levels by promoting their excretion in urine, leading to benefits like reduced heart failure (HF) hospitalizations in patients with type 2 diabetes (T2DM) and cardiovascular (CV) risks.
- Clinical trials like DAPA-HF and EMPEROR-Reduced demonstrate that SGLT2i medications (dapagliflozin and empagliflozin) significantly reduce CV mortality and HF hospitalizations in heart failure patients, whether they have T2DM or not.
- Recent studies, including EMPEROR-Preserved and DELIVER, also support the effectiveness of SGLT2is in treating heart
Dilated sinuses of Valsalva subsequent to type A dissection surgery: Is reoperation inevitable?
Turk Gogus Kalp Damar Cerrahisi Derg
April 2023
Department of Cardiovascular Surgery, Health Sciences University, Dr. Siyami Ersek Chest Heart and Vascular Surgery Training and Research Hospital, Istanbul, Türkiye.
Background: This study aims to investigate the dilation of sinus valsalva in patients who underwent aortic repair due to type A aortic dissection and to evaluate its progression.
Methods: Between January 2004 and December 2019, a total of 68 patients (50 males, 18 females; mean age: 54.2±10.